Rictor, an mTORC2 Protein, Regulates Murine Lymphatic Valve Formation Through the AKT-FOXO1 Signaling
Arteriosclerosis, Thrombosis, and Vascular Biology · 2024
DOI: 10.1161/atvbaha.124.321164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2024. Verfasst von Richa Banerjee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa. Hauptthemen laut MEDLINE: Rapamycin-Insensitive Companion of mTOR Protein, Proto-Oncogene Proteins c-akt, Forkhead Box Protein O1, Lymphatic Vessels. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Lymphatic valves are specialized structures in collecting lymphatic vessels and are crucial for preventing retrograde lymph flow. Mutations in valve-forming genes have been clinically implicated in the pathology of congenital lymphedema. Lymphatic valves form when oscillatory shear stress from lymph flow signals through the PI3K/AKT pathway to promote the transcription of valve-forming genes that trigger the growth and maintenance of lymphatic valves. Conventionally, in many cell types, AKT is phosphorylated at Ser473 by the mTORC2 (mammalian target of rapamycin complex 2). However, mTORC2 has not yet been implicated in lymphatic valve formation. METHODS: In vivo and in vitro techniques were used to investigate the role of Rictor , a critical component of mTORC2, in lymphatic endothelium. RESULTS: Here, we showed that embryonic and postnatal lymphatic deletion of Rictor , a critical component of mTORC2, led to a significant decrease in lymphatic valves and prevented the maturation of collecting lymphatic vessels. RICTOR knockdown in human dermal lymphatic endothelial cells not only reduced the level of activated AKT and the expression of valve-forming genes under no-flow conditions but also abolished the upregulation of AKT activity and valve-forming genes in response to oscillatory shear stress. We further showed that the AKT target, FOXO1 (forkhead box protein O1), a repressor of lymphatic valve formation, had increased nuclear activity in Rictor knockout mesenteric lymphatic endothelial cells in vivo. Deletion of Foxo1 in Rictor knockout mice restored the number of valves to control levels in lymphatic vessels of the ear and mesentery. CONCLUSIONS: Our work identifies a novel role for RICTOR in the mechanotransduction signaling pathway, wherein it activates AKT and prevents the nuclear accumulation of the valve repressor, FOXO1, which ultimately enables the formation and maintenance of lymphatic valves.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa.
ORCID-Profile: Richa Banerjee, Drishya Iyer, Joshua P Scallan, Ying Yang
Förderung
- NHLBI NIH HHS
Zitieren
APA
Banerjee, R., Knauer, L. A., Iyer, D., Barlow, S. E., Shalaby, H., Dehghan, R., Scallan, J. P., & Yang, Y. (2024). Rictor, an mTORC2 Protein, Regulates Murine Lymphatic Valve Formation Through the AKT-FOXO1 Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.321164
Vancouver
Banerjee R, Knauer LA, Iyer D, Barlow SE, Shalaby H, Dehghan R, et al. Rictor, an mTORC2 Protein, Regulates Murine Lymphatic Valve Formation Through the AKT-FOXO1 Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024. doi:10.1161/atvbaha.124.321164
BibTeX
@article{Banerjee2024,
author = {Banerjee, Richa and Knauer, Luz A and Iyer, Drishya and Barlow, Sara E and Shalaby, Hanan and Dehghan, Razieh and Scallan, Joshua P and Yang, Ying},
title = {Rictor, an mTORC2 Protein, Regulates Murine Lymphatic Valve Formation Through the AKT-FOXO1 Signaling},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2024},
doi = {10.1161/atvbaha.124.321164}
}
EUVIMED